AU752919B2 - Nitrate salt of anti-ulcer medicine - Google Patents
Nitrate salt of anti-ulcer medicine Download PDFInfo
- Publication number
- AU752919B2 AU752919B2 AU30303/99A AU3030399A AU752919B2 AU 752919 B2 AU752919 B2 AU 752919B2 AU 30303/99 A AU30303/99 A AU 30303/99A AU 3030399 A AU3030399 A AU 3030399A AU 752919 B2 AU752919 B2 AU 752919B2
- Authority
- AU
- Australia
- Prior art keywords
- salt
- nitrate salt
- free valence
- nitrate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000002823 nitrates Chemical class 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 230000000767 anti-ulcer Effects 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 208000025865 Ulcer Diseases 0.000 claims description 16
- 230000002496 gastric effect Effects 0.000 claims description 16
- 231100000397 ulcer Toxicity 0.000 claims description 16
- 201000006549 dyspepsia Diseases 0.000 claims description 15
- 230000002178 gastroprotective effect Effects 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 229910017604 nitric acid Inorganic materials 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 5
- 150000003180 prostaglandins Chemical class 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 150000001621 bismuth Chemical class 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000012047 saturated solution Substances 0.000 claims description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 3
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 3
- 239000003699 antiulcer agent Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229960001380 cimetidine Drugs 0.000 description 9
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960000620 ranitidine Drugs 0.000 description 9
- 239000002243 precursor Substances 0.000 description 7
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical group [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 6
- -1 compound salts Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical group S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical group N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000001262 anti-secretory effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229950002377 ebrotidine Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical group [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical group COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017982 Gastrointestinal necrosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical group COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical group NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical group CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98MI000442A IT1299198B1 (it) | 1998-03-05 | 1998-03-05 | Sali nitrati di farmaci antiulcera |
| ITMI98A000442 | 1998-03-05 | ||
| PCT/EP1999/001226 WO1999045004A1 (en) | 1998-03-05 | 1999-02-25 | Nitrate salt of anti-ulcer medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3030399A AU3030399A (en) | 1999-09-20 |
| AU752919B2 true AU752919B2 (en) | 2002-10-03 |
Family
ID=11379185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU30303/99A Ceased AU752919B2 (en) | 1998-03-05 | 1999-02-25 | Nitrate salt of anti-ulcer medicine |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6503929B1 (enExample) |
| EP (1) | EP1068196B1 (enExample) |
| JP (1) | JP2002505328A (enExample) |
| KR (1) | KR20010041522A (enExample) |
| CN (1) | CN1249053C (enExample) |
| AT (1) | ATE273297T1 (enExample) |
| AU (1) | AU752919B2 (enExample) |
| BR (1) | BR9908428A (enExample) |
| CA (1) | CA2322493A1 (enExample) |
| DE (1) | DE69919341T2 (enExample) |
| DK (1) | DK1068196T3 (enExample) |
| ES (1) | ES2226357T3 (enExample) |
| HU (1) | HUP0100853A3 (enExample) |
| IL (1) | IL137721A0 (enExample) |
| IT (1) | IT1299198B1 (enExample) |
| PT (1) | PT1068196E (enExample) |
| RU (1) | RU2228331C2 (enExample) |
| SI (1) | SI1068196T1 (enExample) |
| WO (1) | WO1999045004A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| WO2000028988A1 (en) | 1998-11-17 | 2000-05-25 | Nitromed, Inc. | Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| CN100486573C (zh) | 1999-12-23 | 2009-05-13 | 硝化医药股份有限公司 | 硝基化的和亚硝基化的环加氧酶-2抑制剂、组合物及其用途 |
| IT1317735B1 (it) * | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
| SE0002476D0 (sv) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
| ATE338544T1 (de) | 2000-12-21 | 2006-09-15 | Nitromed Inc | Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren |
| GB2393189B (en) * | 2001-07-19 | 2005-06-15 | Trikon Holdings Ltd | Depositing a tantalum film |
| US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| US7211598B2 (en) | 2002-06-28 | 2007-05-01 | Nitromed, Inc. | Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| CA2491127A1 (en) | 2002-07-03 | 2004-01-15 | Nitromed, Inc. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| CA2493156A1 (en) | 2002-07-29 | 2004-02-05 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| CA2493618A1 (en) * | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| RU2304967C2 (ru) * | 2005-05-26 | 2007-08-27 | Государственное общеобразовательное учреждение высшего профессионального образования Казанский государственный медицинский университет | Способ лечения язвенной болезни желудка и двенадцатиперстной кишки |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1397436A (en) * | 1972-09-05 | 1975-06-11 | Smith Kline French Lab | Heterocyclic n-cyanoguinidines |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4375547A (en) | 1980-10-02 | 1983-03-01 | Eli Lilly And Company | N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine |
| EP0224612A1 (de) * | 1985-12-05 | 1987-06-10 | HEUMANN PHARMA GMBH & CO | Verfahren zur Herstellung von N-Cyano-N'-methyl-N"[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidin |
| ATE86619T1 (de) * | 1987-04-06 | 1993-03-15 | Heumann Pharma Gmbh & Co | Verfahren zur herstellung von nitroethenderivaten. |
| TW205041B (enExample) * | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co |
-
1998
- 1998-03-05 IT IT98MI000442A patent/IT1299198B1/it active IP Right Grant
-
1999
- 1999-02-25 US US09/622,068 patent/US6503929B1/en not_active Expired - Fee Related
- 1999-02-25 CA CA002322493A patent/CA2322493A1/en not_active Abandoned
- 1999-02-25 SI SI9930655T patent/SI1068196T1/xx unknown
- 1999-02-25 AU AU30303/99A patent/AU752919B2/en not_active Ceased
- 1999-02-25 DE DE69919341T patent/DE69919341T2/de not_active Expired - Fee Related
- 1999-02-25 IL IL13772199A patent/IL137721A0/xx unknown
- 1999-02-25 EP EP99911708A patent/EP1068196B1/en not_active Expired - Lifetime
- 1999-02-25 JP JP2000534547A patent/JP2002505328A/ja not_active Withdrawn
- 1999-02-25 ES ES99911708T patent/ES2226357T3/es not_active Expired - Lifetime
- 1999-02-25 BR BR9908428-7A patent/BR9908428A/pt not_active Application Discontinuation
- 1999-02-25 WO PCT/EP1999/001226 patent/WO1999045004A1/en not_active Ceased
- 1999-02-25 PT PT99911708T patent/PT1068196E/pt unknown
- 1999-02-25 HU HU0100853A patent/HUP0100853A3/hu unknown
- 1999-02-25 AT AT99911708T patent/ATE273297T1/de not_active IP Right Cessation
- 1999-02-25 KR KR1020007009693A patent/KR20010041522A/ko not_active Abandoned
- 1999-02-25 CN CNB998035343A patent/CN1249053C/zh not_active Expired - Fee Related
- 1999-02-25 DK DK99911708T patent/DK1068196T3/da active
- 1999-02-25 RU RU2000122968/04A patent/RU2228331C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI980442A1 (it) | 1999-09-05 |
| DK1068196T3 (da) | 2004-11-29 |
| PT1068196E (pt) | 2004-10-29 |
| ES2226357T3 (es) | 2005-03-16 |
| WO1999045004A1 (en) | 1999-09-10 |
| KR20010041522A (ko) | 2001-05-25 |
| US6503929B1 (en) | 2003-01-07 |
| DE69919341D1 (de) | 2004-09-16 |
| IL137721A0 (en) | 2001-10-31 |
| IT1299198B1 (it) | 2000-02-29 |
| EP1068196A1 (en) | 2001-01-17 |
| HUP0100853A3 (en) | 2003-01-28 |
| DE69919341T2 (de) | 2005-09-08 |
| JP2002505328A (ja) | 2002-02-19 |
| HUP0100853A2 (hu) | 2001-10-28 |
| AU3030399A (en) | 1999-09-20 |
| EP1068196B1 (en) | 2004-08-11 |
| CA2322493A1 (en) | 1999-09-10 |
| CN1249053C (zh) | 2006-04-05 |
| BR9908428A (pt) | 2000-10-31 |
| RU2228331C2 (ru) | 2004-05-10 |
| SI1068196T1 (en) | 2004-12-31 |
| ATE273297T1 (de) | 2004-08-15 |
| CN1291982A (zh) | 2001-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU752919B2 (en) | Nitrate salt of anti-ulcer medicine | |
| EP0268956B1 (en) | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | |
| ES2489645T3 (es) | Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión | |
| AU757155B2 (en) | Pharmaceutical compositions for ulcer | |
| BRPI0719828A2 (pt) | Mono-hidrato de 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamo-il} amino)-3-fluorofenóxi]-n-metilpiridina-2-carboxamid a | |
| TW470742B (en) | Benzimidazole derivatives, preparation and pharmaceutical compositions thereof | |
| JPS6229566A (ja) | 新規グアニジノメチル安息香酸誘導体 | |
| JP2002505328A5 (enExample) | ||
| JPS62252780A (ja) | 新規なインデノチアゾ−ル誘導体及びその製造法 | |
| JPH10510258A (ja) | セフェム化合物およびその医薬用途 | |
| PT91198B (pt) | Processo para a preparacao de derivados antiulcera da (alquilditio) quinolina | |
| JPS63270663A (ja) | ピリジルアルキルアミンのアルキルカルボキシアミド類、その製造及び医薬組成物 | |
| JPS62108863A (ja) | ２−ピリジル酢酸誘導体、その製法およびそれを含む医薬 | |
| DE2950990A1 (de) | 7 alpha -methoxycephalosporinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten | |
| US3324102A (en) | Water-soluble benzimidazole-containing coordination compounds and methods relating thereto | |
| US3326753A (en) | Benzimidazole anthelmintic compositions and method of use | |
| JPS6330462A (ja) | 新規グアニジノメチルベンツアミド誘導体およびそれを有効成分とする抗潰瘍剤 | |
| DK158673B (da) | Analogifremgangsmaade til fremstilling af cephalosporinforbindelser. | |
| JPS59216875A (ja) | 新規ｎ−シアノ−ホルムアミジン、その製法及びこれを含有するヒスタミンｈ↓２−レセプタ−「きつ」抗剤 | |
| JPS5885895A (ja) | セフアロスポリン誘導体および経口投与用細菌感染症治療剤 | |
| JPH01319488A (ja) | テトラヒドロイミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤 | |
| JPS62123115A (ja) | 胃腸の細胞保護剤 | |
| JPH03148283A (ja) | チアゾール誘導体またはその塩ならびにこれらを含有する抗潰瘍剤 | |
| JPH06184153A (ja) | 新規なフェノチアジン化合物及びその塩、それらの製法並びにそれらを有効成分とする消化性潰瘍治療剤 | |
| JPWO1990000544A1 (ja) | 置換アセトアミド誘導体およびそれを含有する抗潰瘍剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |